NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

NCPE Director to make critical submission on proposed orphan drug amendment

By Mindo - 05th May 2019

The Clinical Director of the National Centre for Pharmacoeconomics (NCPE) will soon submit a document in opposition to a proposed legislative amendment to allow for the fast-track of orphan drug assessments.

Speaking to the Medical Independent (MI) following his address at the recent Access to Medicines Ireland annual conference in the RCSI, Prof Michael Barry said the amendment to the Health (Pricing and Supply of Medical Goods) Act 2013 would have negative consequences if passed.

He told the conference he had written a submission on the amendment. “I will be submitting it… to suggest that this is a really bad idea.”

“The amendment suggests, or proposes, that we wouldn’t use the normal evaluation process for drugs for rare diseases,” Prof Barry told MI. “So we wouldn’t assess the cost-effectiveness of those medications. That’s a pretty fundamental change.

“The problem I have with it – I believe if we are using taxpayers’ money to pay for any medicines, we should know the value of those medicines and we should assess the value of those medicines.

“It becomes particularly important for drugs for rare diseases, because they are very expensive medications, sometimes over €500,000 per patient per year, with budget impacts running into the millions.”

Prof Michael Barry

The amendment is proposed by Fianna Fáil spokesperson on Primary Care and Community Health Services, Deputy John Brassil.

Prof Barry said the amendment was “well-intentioned”, but “unfortunately I think it is going to do the opposite of what it is trying to achieve”.

“If we are not assessing a big group of drugs, with high cost, high budget impact, then by definition if we make them available, we will be paying more – so we increase drug expenditure,” he said.

“That means there would be less money to pay for drugs going forward. So that will reduce access to drugs, including drugs for rare disease.”

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read